River Global Investors LLP Has $1.34 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

River Global Investors LLP lowered its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 39.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,706 shares of the medical equipment provider's stock after selling 8,378 shares during the period. River Global Investors LLP's holdings in Zimmer Biomet were worth $1,342,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. Roman Butler Fullerton & Co. bought a new position in shares of Zimmer Biomet in the 4th quarter valued at about $473,000. Geode Capital Management LLC boosted its position in Zimmer Biomet by 2.6% during the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock valued at $524,942,000 after purchasing an additional 125,852 shares during the last quarter. M&T Bank Corp grew its stake in Zimmer Biomet by 48.4% in the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider's stock valued at $2,884,000 after purchasing an additional 8,709 shares in the last quarter. KLCM Advisors Inc. acquired a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $7,825,000. Finally, Peddock Capital Advisors LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $654,000. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Price Performance

Zimmer Biomet stock traded down $3.24 during mid-day trading on Wednesday, reaching $104.10. 2,123,682 shares of the company were exchanged, compared to its average volume of 1,914,477. The firm has a market cap of $20.72 billion, a PE ratio of 23.39, a PEG ratio of 1.95 and a beta of 1.04. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The company has a fifty day simple moving average of $105.68 and a 200-day simple moving average of $107.08. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90.

Remove Ads

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the company earned $2.20 EPS. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

Analysts Set New Price Targets

ZBH has been the topic of a number of recent analyst reports. Raymond James lowered their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Truist Financial restated a "hold" rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Royal Bank of Canada lowered their price target on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Finally, Stifel Nicolaus upped their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $124.15.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.95% of the stock is currently owned by company insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.